Medications Development for the Treatment of Pregnant/Postpartum Women with Substance Related Disorders and/or In Utero Substance Exposed Neonates (R01)
Post Date
March 3rd 2009
Application Due Date
May 7th 2012
Funding Opportunity Number
PA-09-106
CFDA Number(s)
93.279
Funding Instrument Type(s)
Grant
Funding Activity Categories
Eligibility Categories
State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Funding
-
Award Range:
$None - $None
Grant Description
Purpose. The purpose of this FOA is to foster the development of novel pharmacological strategies for the treatment of pregnant/postpartum women with Substance Related Disorders (SRDs) and/or in utero substance exposed neonates. To that end, this FOA issued by NIDA, National Institutes of Health, will encourage applications to implement preclinical and clinical research directed towards: 1) the identification, evaluation, and development of safe and effective novel pharmacotherapies (e.g., new chemical entities or immunotherapies) for the treatment of pregnant/postpartum women with SRDs and/or in utero substance exposed neonates, and/or 2) the evaluation of the safety and efficacy of FDA approved medications (e.g., medications approved for a different indication) for the treatment of pregnant/postpartum women with SRDs and/or in utero substance exposed neonates. Mechanism of Support. This FOA will use the NIH Research Project Grant (R01) mechanism and runs in parallel with a FOA of identical scientific scope, PA-09-107 that encourages applications under the Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
- More Information:
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: